

# Masako Sasaki

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/5803397/publications.pdf>

Version: 2024-02-01

16  
papers

354  
citations

840776

11  
h-index

940533

16  
g-index

16  
all docs

16  
docs citations

16  
times ranked

590  
citing authors

| #  | ARTICLE  | IF  | CITATIONS |
|----|--|-----|-----------|
| 1  | Design, Synthesis, and Biological Evaluation of a Novel Series of 4-Guanidinobenzoate Derivatives as Enteropeptidase Inhibitors with Low Systemic Exposure for the Treatment of Obesity. <i>Journal of Medicinal Chemistry</i> , 2022, 65, 8456-8477.  | 6.4 | 4         |
| 2  | Design and synthesis of a monocyclic derivative as a selective ACC1 inhibitor by chemical modification of biphenyl ACC1/2 dual inhibitors. <i>Bioorganic and Medicinal Chemistry</i> , 2021, 35, 116056.   | 3.0 | 2         |
| 3  | Design and Synthesis of Novel Spiro Derivatives as Potent and Reversible Monoacylglycerol Lipase (MAGL) Inhibitors: Bioisosteric Transformation from 3-Oxo-3,4-dihydro-2H-benzo[1,4]oxazin-6-yl Moiety. <i>Journal of Medicinal Chemistry</i> , 2021, 64, 11014-11044.   | 6.4 | 18        |
| 4  | Selective Acetyl-CoA Carboxylase 1 Inhibitor Improves Hepatic Steatosis and Hepatic Fibrosis in a Preclinical Nonalcoholic Steatohepatitis Model. <i>Journal of Pharmacology and Experimental Therapeutics</i> , 2021, 379, 280-289.   | 2.5 | 11        |
| 5  | Discovery and characterization of a small molecule enteropeptidase inhibitor, SCO-792. <i>Pharmacology Research and Perspectives</i> , 2019, 7, e00517.  | 2.4 | 13        |
| 6  | The identification and pharmacological evaluation of potent, selective and orally available ACC1 inhibitor. <i>Bioorganic and Medicinal Chemistry Letters</i> , 2019, 29, 126749.  | 2.2 | 8         |
| 7  | Design and synthesis of a novel 1H-pyrrolo[3,2-b]pyridine-3-carboxamide derivative as an orally available ACC1 inhibitor. <i>Bioorganic and Medicinal Chemistry</i> , 2019, 27, 2521-2530.   | 3.0 | 6         |
| 8  | Design, Synthesis, and Evaluation of (4R)-1-{3-[2-( <sup>18</sup> F)Fluoro-4-methylpyridin-3-yl]phenyl}-4-[4-(1,3-thiazol-2-ylcarbonyl)piperazin-1-yl]pyrrolidin-2-one ([ <sup>18</sup> F]T-401) as a Novel Positron-Emission Tomography Imaging Agent for Monoacylglycerol Lipase. <i>Journal of Medicinal Chemistry</i> , 2019, 62, 2362-2375. | 6.4 | 26        |
| 9  | Discovery of Novel Selective Acetyl-CoA Carboxylase (ACC) 1 Inhibitors. <i>Journal of Medicinal Chemistry</i> , 2018, 61, 1098-1117.   | 6.4 | 18        |
| 10 | Design, Synthesis, and Evaluation of Piperazinyl Pyrrolidin-2-ones as a Novel Series of Reversible Monoacylglycerol Lipase Inhibitors. <i>Journal of Medicinal Chemistry</i> , 2018, 61, 9205-9217.  | 6.4 | 49        |
| 11 | Discovery of Novel and Potent Stearoyl Coenzyme A Desaturase 1 (SCD1) Inhibitors as Anticancer Agents. <i>Bioorganic and Medicinal Chemistry</i> , 2017, 25, 3768-3779.  | 3.0 | 27        |
| 12 | In vitro and in vivo antitumor activities of T-3764518, a novel and orally available small molecule stearoyl-CoA desaturase 1 inhibitor. <i>European Journal of Pharmacology</i> , 2017, 807, 21-31.   | 3.5 | 16        |
| 13 | Symmetrical approach of spiro-pyrazolidinediones as acetyl-CoA carboxylase inhibitors. <i>Bioorganic and Medicinal Chemistry Letters</i> , 2012, 22, 4769-4772.  | 2.2 | 34        |
| 14 | Design, synthesis, and structure-activity relationships of novel spiro-piperidines as acetyl-CoA carboxylase inhibitors. <i>Bioorganic and Medicinal Chemistry Letters</i> , 2012, 22, 3643-3647.  | 2.2 | 44        |
| 15 | Discovery of a 3-Pyridylacetic Acid Derivative (TAK-100) as a Potent, Selective and Orally Active Dipeptidyl Peptidase IV (DPP-4) Inhibitor. <i>Journal of Medicinal Chemistry</i> , 2011, 54, 831-850.  | 6.4 | 51        |
| 16 | Discovery of potent, selective, and orally bioavailable quinoline-based dipeptidyl peptidase IV inhibitors targeting Lys554. <i>Bioorganic and Medicinal Chemistry</i> , 2011, 19, 4482-4498.  | 3.0 | 27        |